The Canadian PBC Society worked with Dr. Puneeta Tandon and her team at the University of Alberta on the Empower Wellness Program. After completing a 12 week program, participants reported clinically meaningful improvements in fatigue and overall quality of life. We are thrilled to see the full study findings in
The Canadian PBC Society is committed to advocating for people living with PBC. In the spring of 2026, 324 people living with PBC from across Canada shared their experiences by completing our 2026 PBC Patient Survey. We are pleased to share an infographic highlighting the survey’s preliminary findings. Click here
Learn more about how AMA/ANA is used for PBC diagnosis and risk stratification. This article was published in the November 2022 issue of Clinics in Liver Disease Vol 26 Issue 4. Read full article here.
In the present large, international retrospective cohort study, liver stiffness assessed by vibration-controlled transient elastography was validated as one of the strongest predictive factors of poor clinical outcome in PBC and was shown to improve the prognostic ability of established biochemical markers of treatment response. Studies to evaluate the prognostic
UK PBC Audit: Critical shortfalls in the management of PBC: results of the first nationwide, population-based study of care delivery across the UK. Presenter: Nadir Abbas Findings from an audit of 8968 PBC patient records in 122 UK hospitals over a one-year period, accessed: accurate diagnosis, treatment, symptom directed therapy,
“Little is known about PBC affecting subjects with heterogeneous genetic backgrounds [4]. Brazil has a population of a highly admixed origin, with varying proportions of Amerindian, African, and European genetic ancestries, shaped by local historical interactions with migrants brought by the slave trade, European settlement, and indigenous populations [5]. In order
Study concludes that triple therapy with UDCA, OCA and fibrates is able to normalise biochemical liver tests and improve pruritus in patients with difficult‐to‐treat PBC. Read full study.
Since OCA (Ocaliva) was approved in the US in 2016 and Canada in 2017, there have been several studies to assess its effectiveness in PBC patients around the world. Here are some links to those studies. Hirschfield, Hansen: OCA improves AST-to-platelet ratio index and GLOBE score in PBC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724188/ Italian
The Canadian Network for Autoimmune Liver disease (CaNAL) is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome. This nationwide registry focuses on high quality long-term follow-up of individual patients. Issue 1: CanNAL patient newsletter.
